Study of Effects of Alogliptin on Diabetic Atherosclerosis by Gray-Scale Median (GSM)

Trial Profile

Study of Effects of Alogliptin on Diabetic Atherosclerosis by Gray-Scale Median (GSM)

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Alogliptin (Primary)
  • Indications Atherosclerosis; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms SPEAD-A GSM
  • Most Recent Events

    • 28 Nov 2017 Status changed from recruiting to completed.
    • 29 May 2017 Status changed from active, no longer recruiting to recruiting.
    • 02 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top